All UK companies at BIO-Europe 2013

UK companies attending BIO-Europe 2013 as part of the official delegation

(Click here to search profiles):

UK stand (booth 68)
Advocates, AMRI UK, Autifony Therapeutics, Avillion, BIA(UK BioIndustry Association), Bristows, Cambridge Biosciences, Canbex Therapeutics, Crescendo Biologics, CrystecPharma, Datatrial, Desktop Genetics, Domainex, e-therapeutics, Epistem, Genetic Microdevices, Glythera, Hypha Discovery, Illingworth Research, Image Analysis, MGB Biopharma, MiNA Therapeutics, Nova Language Services, Novozymes Biopharma, Ockham Oncology, Oxford Biomedica, Purolite,QCTR, Quay Pharma, Selcia, Sphere Fluidics, Sygnature Discovery, Synpromics. UK Trade & Investment London

UK Exhibitors
BioPartner, UK stand, booth #68; Almac Group, booth #64; cddi, booth #1
Allergy Therapeutics, Cobra Biologics, Evaluate, Fujifilm Diosynth Biotechnologies, GlobalData  

UK companies associated with the delegation*:
Almac Discovery, Almac Group, Amdipharm Mercury Co., Appleyard Lees, Atebion,cddi, Coulter Partners, Covington & Burling, Entrepreneurs Fund, Epistem, Finvector, Fusion Antibodies, Galen, Glide Pharma, Haemostatix, HitGen, KWS BioTest, Kymab, Mewburn Ellis, Molecular Profiles, Patheon, Polytherics, Present Value, ProImmune, ProPharma Partners, Prosonix, Q Chip, Summit, SYNthesis med chem, UCB Celltech, Warner Chilcott (Actavis)

UK Presenting Companies:
AstraZeneca, Canbex Therapeutics, Crescendo Biologics, e-therapeutics, Genetic Microdevices, GlaxoSmithKline, GT Biologics, Heptares Therapeutics, MGB Biopharma, Midatech Group, MiNA Therapeutics, Nanomerics, Oxford BioTherapeutics, PlaqueTec, Sareum, The Institute of Cancer Research, Xention
See Networking Programme for timings 

London Trade Mission:
Activiomics, Alacrita, Autifony Therapeutics, Canbex Therapeutics, CellMedica, Desktop Genetics, Domainex, Genetic Microdevices, Hypha Discovery, Image Analysis, Lord Mayor's Office, MiNA Therapeutics, Nanomerics, Phastar, Polytherics, Proxima Concepts/Diabetology, UK Trade & Investment London, Valirx

All attending UK companies:
3M Healthcare, 80th Atom, Abingworth, Acacia Pharma, Activiomics, Advocates, Alacrita, Allergan Holdings, Allergy Therapeutics, Almac Discovery, Almac Group, Amdipharm Mercury Co., AMRI UK, Apex healthcare Consulting, Apitope, Appleyard Lees, Aptuit Glasgow, AstraZeneca, Atebion, Atlantic Healthcare, Aurelia Bioscience, Autifony Therapeutics, Avillion, BIA, Bicycle Therapeutics, Bio-Images Group, BioFocus, Bio-Outsource, BioPartner, Biopharm Insights, Biopharma Technology, Bioreliance, Biosceptre International, Biotecnol, Brainwave Discovery, Bristol-Myers Squibb, Bristows, Cambridge Bioscience, Canbex Therapeutics, Cancer Research Technology, cddi, CellMedica, Charles River, Circassia, Clinigen, Cmed Clinical Services, Cobra Biologics, College Hill Life Sciences, Consilient Health, Convergence Pharmaceuticals, Coulter Partners, Covance, Covington & Burling, Crescendo Biologics, Current Partnering, CrystecPharma, Datatrial, Decision Resources Group, Desktop Genetics, Domainex, Drug Delivery International, Duke Street, Durbin, Edinburgh BioQuarter, Egamid, Eisai, EMBL- European Bioinformatics Institute (EBI), Endomagnetics, Entrepreneurs Fund, Epistem, ERA Consulting, Ergomed Clinical Research, e-Therapeutics, Evaluate, Evgen Pharma, Ergomed Clinical Research, Evaluate, f-star, Ferghana Partners, Fidelity Biosciences, FinVecor, Fujifilm Diosynth Biotechnologies, Fusion Antibodies, Galen, GE Healthcare, George James, Genetic Microdevices, Gilead Sciences, GlaxoSmithKline, Gleacher Shacklock, GLG (Gerson Lehrman Group), Glide Pharma, GlobalData, Glythera, GT Biologics, GW Pharmaceuticals, Haemostatix, Heptares Therapeutics, Heraeus, HitGen, Hologic | Gen-Probe, Horizon Discovery, Hypha Discovery, ICT Biosciences, Illingworth Research, Image Analysis, Immune Targeting Systems, Immunocore, Imperial Innovations, IMS Health, INC Research, Infinata, Informa, Isogenica, Kings college London, KWS BioTest, Kymab, Liftstream, Medius Asociates, Mewburn Ellis, MGB Biopharma, Midatech Group, MiNA Therapeutics, MOFgen, Molecular Profiles, Moorfields Pharmaceuticals, MRC Technology, MSD, Mundipharma International, MVM Life Science Partners, Nanomerics, Nature, NDA Group, Newcastle Biomedicine, NextPharma, Norgine, Nova Language Services, Novella Clinical, Novozymes Biopharma, OBN, Ockham Oncology, One Nucleus, Ono Pharma UK, Orbona Pharma, Oxford BioMedica, Oxford BioTherapeutics, Oxyrane, Parexel, Patheon, Peakdale Molecular, PGXIS, PharmaTelevision, Pharmaterials, PharmaVentures, PharmaWave, Phastar, Pinsent Masons, PlaqueTec, Plethora Solutions, Polytherics, PRA, Present Value, ProFactor Pharma, ProImmune, ProPharma Partners, Prosonix, ProStrakan, Proxima Concepts/Diabetology, PsiOxus Therapeutics, Purolite, Queen Mary University, QCTR, Q Chip, Quay Pharma, Quintiles, R&D Focus/IMS Health, RedX Pharma, ReNeuron, Roslin Cells, RUSSLAN Clinical Research, Sage Healthcare, Samedan, Sareum, Scottish Development International, Scrip Intelligence, Selcia, SGS Vitrology, Shield Therapeutics, Shionogi, Shire Pharmaceutical, SpenglerFox, Sphere Fluidics, SQC Clinical Trial, Strathclyde University, Sygnature Discovery, Symbiosis, Synpromics, SYNthesis med chem, Talentmark, Teijin Pharma, The Institute of Cancer Research, The Pink Sheet, Thiologics, Theradex, Thomson Reuters, TPP Global Development, TRN - The Research Network, UCB Celltech, UCL Business, UK Trade & Investment London, University of Dundee, University of Edinburgh, University of Nottingham, University of Sussex, Valirx, Vectura, Virttu Biologics, Visium Asset Management, VueKlar Cardiovascular, Warner Chilcott (Actavis), Warwick Ventures, Wellcome Trust Sanger Institute, Wragge & Co, Xention (224)

Join them here!

*BioPartnership Programme members are hyperlinked

Correct at 31st October 2013